-
公开(公告)号：US12257288B2
公开(公告)日：2025-03-25
申请号：US16464105
申请日：2017-12-01
Applicant: BIOVERATIV THERAPEUTICS INC. , SWEDISH ORPHAN BIOVITRUM AB
Inventor： Jennifer Dumont , Nisha Jain , Stefan Lethagen
Abstract: The present disclosure provides methods inducing immune tolerance in a human, comprising administering to the human an effective amount of a composition or a chimeric protein comprising a clotting factor and an Fc region.
-
公开(公告)号：US12173307B2
公开(公告)日：2024-12-24
申请号：US17356980
申请日：2021-06-24
Inventor： Mukesh Mayani , Tongyao Liu , Ayman Ismail
IPC: C12N15/86
Abstract: Viral vector production processes and methods of purifying a viral vector from a host cell are provided herein.
-
公开(公告)号：US20240400645A1
公开(公告)日：2024-12-05
申请号：US18656168
申请日：2024-05-06
Applicant: BIOVERATIV THERAPEUTICS INC.
Inventor： Ekta SETH CHHABRA , Alison INNES , Dan RUDIN , Kara RICE , Nancy WONG , Suresh KATRAGADDA
IPC: C07K14/755 , A61K38/00 , A61P7/04
Abstract: The present disclosure provides a method of treating hemophilia A in a human subject in need thereof comprising administering to the subject a chimeric polypeptide comprising (i) a factor VIII (FVIII) protein and (ii) a von Willebrand factor (VWF) fragment comprising a D′ domain of VWF and a D3 domain of VWF at a dosing interval.
-
公开(公告)号：US12134632B2
公开(公告)日：2024-11-05
申请号：US18153669
申请日：2023-01-12
Applicant: BIOVERATIV THERAPEUTICS INC.
Inventor： Glen Bolton , Keith Selvitelli
Abstract: The present invention is directed to a method of inactivating virus that is present during production of a polypeptide of interest. In particular, the present invention is directed to a method of on-column virus inactivation using a low pH and high salt wash solution that effectively inactivates viruses with minimum recovery loss of the polypeptide.
-
公开(公告)号：US20240358800A1
公开(公告)日：2024-10-31
申请号：US18632038
申请日：2024-04-10
Applicant: BIOVERATIV THERAPEUTICS INC.
Inventor： Tyler CARLAGE , Randall MAULDIN , Timothy MCCOY , Loubna Mzaalak TAZI
CPC classification number: A61K38/37 , A61K9/0019 , A61K9/19 , A61K47/02 , A61K47/10 , A61K47/183 , A61K47/22 , A61K47/26
Abstract: The present disclosure provides pharmaceutical compositions of a chimeric protein comprising a factor VIII (FVIII) polypeptide and a von Wilobrand factor (VWF) polypeptide. Also disclosed are pharmaceutical kits and methods of using the disclosed pharmaceutical compositions to treat hemophilia A.
-
Patent Agency Ranking
公开(公告)号：US20240350672A1
公开(公告)日：2024-10-24
申请号：US18617239
申请日：2024-03-26
Applicant: BIOVERATIV THERAPEUTICS INC.
Inventor： Tongyao LIU , Ekta Seth CHHABRA , Siyuan TAN
IPC: A61K48/00 , A61K38/00 , A61P7/04 , C07K14/755 , C12N15/85
CPC classification number: A61K48/0058 , A61P7/04 , C07K14/755 , C12N15/85 , A61K38/00
Abstract: The present disclosure provides codon optimized Factor VIII sequences, vectors, and host cells comprising codon optimized Factor VIII sequences, polypeptides encoded by codon optimized Factor VIII sequences, and methods of producing such polypeptides.
-
公开(公告)号：US20230338344A1
公开(公告)日：2023-10-26
申请号：US18191293
申请日：2023-03-28
Applicant: Bioverativ Therapeutics Inc.
Inventor： Pauline RIMMELÉ , Dieter SCHMOLL , Yannis HARA
IPC: A61K31/4365 , A61K31/404 , A61K31/17 , A61P7/06
CPC classification number: A61K31/4365 , A61K31/404 , A61K31/17 , A61P7/06
Abstract: This disclosure to methods for treating or preventing particular symptoms and disorders which are associated with blood disorders using AMPK activators. Also disclosed are pharmaceutical composition comprising an AMPK activator for use in said methods.
-
8.发明申请公开(公告)号：US20230002828A1
公开(公告)日：2023-01-05
申请号：US17681435
申请日：2022-02-25
Applicant: Bioverativ Therapeutics Inc. , Puget Sound Blood Center
Inventor： Haiyan JIANG , Tongyao LIU , Sriram KRISHNAMOORTHY , Neil JOSEPHSON , Glenn PIERCE
IPC: C12Q1/6883 , A61K38/21 , A61K39/00 , A61K38/37 , C07K14/755 , A61K47/68
Abstract: The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
-
公开(公告)号：US20220296469A1
公开(公告)日：2022-09-22
申请号：US17835663
申请日：2022-06-08
Applicant: BIOVERATIV THERAPEUTICS INC.
Inventor： Christine P. JANSON , Ethan B. JACOBY , Frederick Carel STEINMANN , Nikhil GANDHI , Chad PRESHER
Abstract: Device containers, such as therapeutic kit containers, are disclosed. In one embodiment, a device container comprises a first member configured to releasably hold a syringe barrel, a second member configured to releasably hold a vial, wherein the second member is coupled to the first member by a first hinge, and a third member configured to releasably hold a vial adapter, wherein the third member is coupled to the second member by a second hinge.
-
公开(公告)号：US20220265780A1
公开(公告)日：2022-08-25
申请号：US17587941
申请日：2022-01-28
Applicant: BIOVERATIV THERAPEUTICS INC.
Inventor： Jennifer A. DUMONT , Susan LOW , Alan J. BITONTI , Glenn PIERCE , Alvin LUK , Haiyan JIANG , Byron MCKINNEY , Matt OTTMER , Jurg SOMMER , Karen NUGENT , Lian LI , Robert PETERS
IPC: A61K38/37 , A61K47/64 , A61K47/68 , C07K14/755 , C07K16/46
Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
-
-
-
-
-
-
-
-
-
Search Results
158
records
(took 0.02 seconds)
